Position statement on the use of bortezomib in multiple myeloma

International Journal of Laboratory Hematology

Volumn 30, Issue 1, 2008, Pages 1-10

  Morgan, G J ^a   Davies, F E ^a   Cavenagh, J D ^b   Jackson, G H ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Bortezomib; Myeloma; Proteasome inhibition; Relapse therapy

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MITOXANTRONE; PROTEASOME INHIBITOR; THALIDOMIDE;

ANEMIA; BLOOD BRAIN BARRIER; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELAPSE; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UNITED KINGDOM; VOMITING;

BORONIC ACIDS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 38049011977     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.01020.x     Document Type: Review

References (40)

1. Adams J. (2004) The proteasome: a suitable antineoplastic target. Nature Reviews Cancer 4, 349 360.
2. Adams J., Palombella V.J., Sausville E.A. et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 59, 2615 2622.
3. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C. Bataille R. (1996) A prospective, randomized trial of autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New England Journal of Medicine 335, 91 97.
4. Bagust A., Haycox A.R., Boland A., Chu P., Morgan G.J., Mujica Mota R., Dubois D. Dhawan R. (2004) Economic evaluation of Bortezomib (Velcade) for relapsed and refractory multiple myeloma. Blood 104, Abstract 268.
5. BCSH guidelines (2003) Guidelines for the use of platelet transfusions. British Journal of Haematology 122, 10 23.
6. Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., Purner M., Less S., Wilson J., Morrison B., Adams J., Schenkein D. Swift R. (2006) Phase 1/11 trial assessing Bortezomib and melphalan cobination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology 24, 937 944.
7. Blade J., Samson D., Reece D. et al. (1998) Criteria for evaluating disease responses and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology 102, 1115 1123.
8. Chanan-Khan A.A., Kaufman J.L., Mehta J., Richardson P.G., Miller K.C., Lonial S., Munshi N.C., Schlossman R., Tariman J. Singhal S. (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109, 2604 2606.
9. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., Brown J., Drayson M.T., Selby PJ. on behalf of the Medical Research Council Adult Leukaemia Working Party (2003) High dose therapy improves the outcome of patients with multiple myeloma: the MRC Myeloma VII randomized trial. New England Journal of Medicine 348, 1875 1883.
10. Davies F.E., Wu P., Jenner M., Srikanth M., Saso R. Morgan G.J. (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 92, 1149 1150.
11. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., Hulin C., Benboubker L., Fuzibet J.G., Renaud M., Moreau P. Avet-Loiseau H. (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91, 1498 1505.
12. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J. Anderson K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research 61, 3071 3076.
13. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., Niesvizky R., Alexanian R., Limentani S.A., Alsina M., Adams J., Kauffman M., Esseltine D.L., Schenkein D.P. Anderson K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology 127, 165 172.
14. Jagannath S., Durie B., Wolf J. et al. (2005a) Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. British Journal of Haematology 129, 776 783.
15. Jagannath S., Barlogie B., Berenson J.R. et al. (2005b) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103, 1195 1200.
16. Landowski T.H., Megli C.J., Nullmeyer K.D., Lynch R.M. Dorr R.T. (2005) Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Research 65, 3828 3836.
17. Lee A.H., Iwakoshi N.N., Anderson K.C. Glimcher L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of National Academy of Science USA 100, 9946 9951.
18. Lonial S., Waller E.K., Richardson P.G. et al. (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106, 3777 3784.
19. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., Wu Z.Q., Borad M.J., Frantzen M., Roussos E., Neeser J., Mikail A., Adams J., Sjak-Shie N., Vescio R.A. Berenson J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumour cells to chemotherapeutic agents. Clinical Cancer Research 9, 1136 1144.
20. MacLennan I.C., Chapman C., Dunn J. Kelly K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 25, 200 205.
21. Mateos M.V., Hernández J., Hernández M., Gutierrez N.C., Palomera L., Fuertes M., Diaz Mediavilla J., Lahuerta J.J., de la Rubia J., Terol M.J., Sureda A., Bargay J., Rivas P., de Arriba F., Alegre A., Oriol A., Carrera D., García Laraña J., Garcia Sanz R., Blade J., Prosper F., Mateo G., Esseltine D.L., van de Velde H. San Miguel J.F. (2006) Bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients: results of a multicenter phase 1/11 study. Blood 108, 2165 2172.
22. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Schlossman R., Munshi N.C., Hideshima T. Anderson K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377 2380.
23. Myeloma Trialists Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. Journal of Clinical Oncology 16, 3832 3842.
24. Oakervee H., Popat R., Curry N. et al. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology 129, 755 762.
25. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S. et al. (2002) Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. Journal of Clinical Oncology 20, 4420 4427.
26. Orlowski R.Z., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., San Miguel J., Robak T., Dmoszynska A., Horvath N., Spicka I., Sutherland H.J., Suvorov A.N., Zhuang S.H., Parekh T., Xiu L., Yuan Z., Rackoff W. Harousseau J.L. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology 25, 3892 38901.
27. Palumbo A., Ambrosini M.T., Benevolo G., Pregno P., Pescosta N., Callea V., Cangialosi C., Caravita T., Morabito F., Musto P., Bringhen S., Falco P., Avonto I., Cavallo F., Boccadoro M. Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109, 2767 2772.
28. Papandreou C.N., Daliani D.D., Nix D. et al. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Journal of Clinical Oncology 22, 2108 2121.
29. Popat R., Oakervee H.E. Foot N. (2005) A Phase I/II study of bortezomib and low dose intravenous melphalan for relapsed myeloma. Blood 106, Abstract 2555.
30. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P. Anderson K.C. (2003) A phase 2 study of bortezomib in relapsed refractory myeloma. New England Journal of Medicine 348, 2609 2617.
31. Richardson P.G., Chanan-Khan A., Schlossman R.L., Munshi N.C., Wen P., Briemberg H., Kuter D., Oaklander A.L., Lonial S., Hassoun H., Doss D., Colson K., McKenney M., Hande K., Koryzna A., Stoklas B., Lunde L., Gorelik S., McAlister C., Freeman C., Warren D., Collins D., Esseltine D., Amato A. Anderson K.C. (2004) Phase II trial of single agent bortezomib in patients with previously untreated multiple myeloma (MM). Blood 104, Abstract 336.
32. Richardson P., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., Harousseau J., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San Miguel J., Blade J., Boccadoro M., Cavenagh J., Dalton W., Boral A., Schenkein D. Anderson K. (2005a) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine 352, 2487 2498.
33. Richardson P., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Hideshima T., Xiao H., Esseltine D., Schenkein D Anderson K.C. for the SUMMIT Investigators 2005b) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106, 2977 2981.
34. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., Singhal S., Siegel D.S., Irwin D., Schuster M., Srkalovic G., Alexanian R., Rajkumar S.V., Limentani S., Alsina M., Orlowski R.Z., Najarian K., Esseltine D., Anderson K.C. Amato A.A. (2006a) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology 24, 3113 3120.
35. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M. Anderson K.C. (2006b) Extended follow-up of a phase 2 trial relapsed refractory myeloma. Cancer 106, 1316 1319.
36. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San Miguel J., Blade J., Boccadoro M., Cavenagh J., Alsina M., Rajkumar S.V., Lacy M., Jakubowiak A., Dalton W., Boral A., Esseltine D.L., Schenkein D. Anderson K.C. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110, 3557 3560.
37. Rosinol L., Oriol A., Mateos M.V., Sureda A., Garcia-Sanchez P., Gutierrez N., Alegre A., Lahuerta J.J., de la Rubia J., Herrero C., Liu X., Van de Velde H., San Miguel J. Blade J. (2007) Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. Journal of Clinical Oncology 25, 4452 4458.
38. Samson D., Gaminara E., Newland A., Van de Pette J., Kearney J., McCarthy D., Joyner M., Aston L., Mitchell T., Hamon M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma. Lancet 2, 882 885.
39. San Miguel J.F., Richardson P., Sonneveld P., Schuster M., Irwin D., Stadmauer E., Facon T., Harousseau J., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., Blade J., Boccadoro M., Cavenagh J., Dalton W., Boral A., Schenkein D Anderson K. (2005) Frequency, characteristics and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 106, 11, Abstract 366.
40. Wang M., Giralt S., Delasalle K., Handy B. Alexanian R. (2007) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12, 235 239.